Considering that the current response time to letrozole in advanced metastatic breast cancer patients is 9.4 months (versus 6 months with tamoxifen) [50,51], a combination of an IGF-IR inhibitor with an aromatase inhibitor may prolong response time significantly. Here, CYP19A1 is linked to breast carcinoma.